Clinical trial
6-Hydroxymethylacylfulvene in Treating Patients With Metastatic Kidney Cancer
NCT00003390 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00003390 |
|---|---|
| Title | 6-Hydroxymethylacylfulvene in Treating Patients With Metastatic Kidney Cancer |
| Official title | A Phase II Trial of 6-Hydroxymethylacylfulvene (MGI-114) in Patients With Advanced Renal Cell Carcinoma |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Drug |
| Interventions | irofulven |
| Start date | Jun 1, 1998 |
| Completion | Aug 1, 2004 |
| First posted | Aug 26, 2004 |
| Last update posted | Jun 21, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: